CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

HP:0002098: Respiratory distressHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (6)

Name (Synonyms) Correlation
drug294 Examine the impact of COVID-19 during pregnancy Wiki 0.71
drug763 Standard Donor Plasma Wiki 0.71
drug680 Rapid diagnostics using Anyplex TMII RV16 Detection Wiki 0.71
drug254 Delayed diagnostics Anyplex TMII RV16 Detection Wiki 0.71
drug552 Nitric Oxide Wiki 0.50
drug225 Convalescent Plasma Wiki 0.25

Correlated MeSH Terms (10)

Name (Synonyms) Correlation
D004417 Dyspnea NIH 0.82
D005335 Fever of Unknown Origin NIH 0.71
D002637 Chest Pain NIH 0.71
D011024 Pneumonia, Viral NIH 0.12
D003141 Communicable Diseases NIH 0.08
D014777 Virus Diseases NIH 0.08
D011014 Pneumonia NIH 0.06
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0100749 Chest pain HPO 0.71
HP:0002090 Pneumonia HPO 0.11

There are 2 clinical trials

Clinical Trials

1 The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial

Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed. In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described. The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.

NCT02538770 Respiratory Virus Infection Fever of Unknown Origin Dyspnea Chest Pain Other: Rapid diagnostics using Anyplex TMII RV16 Detection Other: Delayed diagnostics Anyplex TMII RV16 Detection
MeSH:Dyspnea Chest Pain Fever of Unknown Origin Virus Diseases
HPO:Chest pain Dyspnea Respiratory distress

Primary Outcomes

Description: The number of days in hospital within one month after randomization

Measure: Duration of hospitalization

Time: One month

Description: Number of days on antimicrobials within one month after randomization

Measure: Antimicrobial consumption

Time: One month

Description: Defined daily doses of antimicrobial agents within one month after randomization

Measure: Antimicrobial consumption

Time: One month

Secondary Outcomes

Measure: Number of radiological examinations

Time: One month

Measure: Cost of other examinations in hospital

Time: One month

2 Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial

The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (COVID-19) originated in China in December 2019. At present, there are no proven interventions to prevent progression of the disease. Some preliminary data on SARS pneumonia suggest that inhaled Nitric Oxide (NO) could have beneficial effects on COVID-19 due to the genomic similarities between this two coronaviruses. In this study we will test whether inhaled NO therapy prevents progression in patients with mild to moderate COVID-19 disease.

NCT04290858 Coronavirus Infections Pneumonia, Viral Dyspnea Drug: Nitric Oxide
MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Dyspnea
HPO:Dyspnea Pneumonia Respiratory distress

Primary Outcomes

Description: The primary outcome will be the proportion of patients with mild COVID2019 who deteriorate to a severe form of the disease requiring intubation and mechanical ventilation. Patients with indication to intubation and mechanical ventilation but concomitant DNI (Do Not Intubate) or not intubated for any other reason external to the clinical judgment of the attending physician will be considered as meeting the criteria for the primary endpoint.

Measure: Reduction in the incidence of intubation and mechanical ventilation

Time: 28 days

Secondary Outcomes

Description: Mortality from all causes

Measure: Mortality

Time: 28 days

Description: Proportion of patients with a negative conversion of RT-PCR from an oropharyngeal or a nasopahryngeal swab

Measure: Negative conversion of COVID-19 RT-PCR from upper respiratory tract

Time: 7 days

Description: Time from initiation of the study to discharge or to normalization of fever (defined as <36.6°C from axillary site, or < 37.2°C from oral site or < 37.8°C from rectal or tympanic site), respiratory rate (< 24 bpm while breathing room air) and alleviation of cough (defined as mild or absent in a patient reported scale of severe >>moderate>>mild>>absent).

Measure: Time to clinical recovery

Time: 28 days

HPO Nodes